GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Land And Improvements

LadRx (STU:CX5) Land And Improvements : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Land And Improvements?

LadRx's land and improvements for the quarter that ended in Dec. 2023 was €0.00 Mil.


LadRx Land And Improvements Historical Data

The historical data trend for LadRx's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Land And Improvements Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Land And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

LadRx Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


LadRx (STU:CX5) Business Description

Traded in Other Exchanges
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines